anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hourly ice resurfacing by gas and propane fueled machines creates high levels of ultrafine and fine particulate matter (PM1) in indoor ice rinks. PM1 exposure may disrupt the normal nitric oxide (NO)/endothelin (ET)-1 vasodilation system and promote atherosclerosis, and/or increase the risk of an acute cardiac event. Our specific aims are 1) to determine whether impaired endothelial-mediated vasodilation and forearm muscle tissue reoxygenation rate and blood volume change (to reactive hyperemia following artery occlusion) is associated with combustion-derived PM1 exposure, and 2) To characterize a PM1 induced mechanism of endothelial dysfunction which occurs via a leukotriene (LT)-associated, airway generated tumor necrosis factor-alpha (TNF-a) mediated pathway. Healthy low PM1 exposed males will be evaluated for endothelial dysfunction before and after artery occlusion using high resolution ultrasound and near-infrared spectroscopy (NIRS), before and after moderate exercise in blinded high and low \[PM1\]. Endothelial dysfunction among chronically PM¬1 exposed ice rink athletes will be determined to evaluate the feasibility of using this population as a model in future studies. TNF-a, IL-8, LTB4, LTC4, LTD4, LTE4, ET-1, NO, and differential cell counts will be measured in sputum and serum. \[PM1\] will be monitored and exposure levels will be typical of indoor ice rinks. LT involvement will be assessed in vivo by double-blind pharmacological manipulation during PM1 exposure during light exercise. Results will demonstrate whether endothelial-mediated vasodilation and muscle hemodynamics are influenced by PM1 exposure, and will elucidate an LT initiated TNF-a mediated pathway in ET-1 upregulation. Our results should provide information for understanding the effects of PM1 exposure on the atherosclerotic process and cardiovascular risk, and give insight to novel treatment and diagnostic modalities.
A detection device for an apnea is provided. The detection device includes a processor, a storage medium, and a transceiver. The transceiver obtains a first unipolar ECG, wherein the first unipolar ECG includes a first data set corresponding to an apnea event and a second data set corresponding to a non-apnea event. The processor accesses and executes a training module and a detection module in the storage medium. The training module uses the first data set and the second data set as training data to train a machine learning model, wherein the training data is a time-domain signal. The detection module obtains a second unipolar ECG of a subject and determines, according to the machine learning model and the second unipolar ECG, whether at least one apnea event is happened on the subject.
This cross-sectional observational study followed the guidelines of the Declaration of Helsinki, and all patients signed an informed consent form approved by the Ethics and Research Committee of the Pontifical Catholic University of Goiás (Pontifícia Universidade Católica de Goiás - PUC-GO). The inclusion criteria were chronic renal patients, who were older than 18 years of age, were part of the hemodialysis program of the Santa Casa de Misericordia de Goiânia (SCMG) hospital, signed the informed consent form and were able to undergo a physical examination. Exclusion criteria were patients on hemodialysis who were not chronic renal patients; patients who refused to participate in the study or could not undergo a physical examination; patients who did not undergo hemodialysis in the week of the study; prior ophthalmic eye disease or surgery; and patients allergic to anesthetic drops or dyes.

Patients were divided into groups according to the days on which they underwent hemodialysis. A total of 39 patients who were on hemodialysis at SCMG for six days in the month of June 2014 were analyzed. The patient's eye fundus was evaluated through direct ophthalmoscopy with a PanOptic device (Welch Allyn). Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.

The variables studied were age, gender, base etiology for CKD, and variations in body weight and IOP before and after hemodialysis. Mean blood pressure (MBP), systolic blood pressure (SBP), diastolic blood pressure (DBP), and ocular perfusion pressure (OPP) were obtained before and after hemodialysis. The following mathematical models were used: MBP = (DBP) + 1/3 (SBP) - (DBP) and OPP = 2/3 (MBP-IOP), as described in the literature (18-20). The data were collected using a form devised for the study from the medical records of the chronic renal patients undergoing hemodialysis at SCMG and registered in the system.

The data were tabulated in a Microsoft© Excel 2007 spreadsheet and analyzed using the Statistical Package for the Social Sciences, version 20 (SPSS, Chicago, IL). The mean, standard deviation, median IOP measurements, blood pressure, and weight were obtained. Data normality was assessed by the Kolmogorov-Smirnov test. The significance of differences between measurements obtained before and after hemodialysis was assessed by the Wilcoxon test. The relationship between IOP and weight was assessed by Pearson's or Spearman's correlation. P-values \<0.05 were considered significant.
Each subject receives either a single dose (SAD) or a multiple dose (MAD) of REM0046127 as oral solution with a concentration of 100 mg/mL REM0046127. The starting dose for the first cohort in the SAD is 35mg up to a maximum of 2000mg at cohort 5. The starting dose for the MAD study is 0,75 of the Maximum Tolerated Dose (MTD) from the SAD.
Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
The advancement of medical treatment and surgical technique, along with the invention of cardiopulmonary bypass, has allowed for long-term survival of patients with cyanotic congenital heart disease (CHD)-with many women with CHD now reaching child-bearing age and wishing to become pregnant. Pregnancy in these women is a major concern as the physiologic adaptations of pregnancy, including an increased circulating volume, increased cardiac output, reduced systemic vascular resistance, and decreased blood pressure, place a substantial load on the cardiovascular system. These changes are essential to meet the increased maternal and fetal metabolic demands and allow for sufficient placental circulation during gestation. However, in women with underlying structural heart conditions, they place an additional hemodynamic burden on the maternal body. Overall, with appropriate risk stratification, pre-conception counseling, and management by specialized cardiologists and high-risk obstetricians, most women with surgically corrected CHDs are expected to carry healthy pregnancies to term with optimization of both maternal and fetal risks. In this article, we describe the current understanding of 5 cyanotic CHDs-Tetralogy of Fallot, Transposition of the Great Arteries, Truncus Arteriosus, Ebstein's Anomaly, and Eisenmenger Syndrome-and explore the specific hemodynamic consequences, maternal and fetal risks, current guidelines, and outcomes of pregnancy in women with these conditions.
The invention relates to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 160 to 170 parts of cordyceps militaris, 70 to 80 parts of lumbricus, 50 to 55 parts of flowers carthami, 30 to 40 parts of frankincense, 50 to 55 parts of centipede, and 50 to 60 parts of rhodiola rosea. The traditional Chinese medicine composition comprises cordyceps militaris, lumbricus, flowers carthami, frankincense, centipede, and rhodiola rosea; the active ingredients of the medicines above supplement each other and actively coordinate, so that the traditional Chinese medicine composition prepared thereby has small side effect, and can be used for treating hemiplegia, favoritism and other symptoms caused by cerebrovascular disease and stroke, and the treatment effect is great. The invention also provides a method for preparing the traditional Chinese medicine composition. The method is characterized in that all components are powdered and then uniformly mixed to obtain the traditional Chinese medicines. The preparation method is simple and easy to carry out; the prepared traditional Chinese medicine composition has good effects on treating hypertension, hyperlipidemia and cerebrovascular disease, and causes small side effect.
FIELD: veterinary science, medicine, cosmetology. SUBSTANCE: the suggested method deals with preliminary washing out placental tissues in water, reducing and isolating a water-soluble composition, moreover, after washing out is over one should carry out rapid tissue freezing up to - 80 - -120 C with liquid nitrogen vapors. Reduction should be conducted in cryogenic mills at -80 C -120 C up to particles size being 20-30 mcm followed by separation of low-molecular fraction in vacuum chambers at the pressure of 0.1 mm mercury column and -10 C - -20 C with subsequent condensation onto cryogenic panels cooled with liquid nitrogen. The method enables to obtain highly efficient biologically active fraction with molecules having native structure at the weight being 300-350 atomic units of weight, not more. EFFECT: higher efficiency. 1 ex, 2 tbl
There is an interest to develop anti-ROBO4 antibodies that can be suitable for the treatment of cancer. The inventors produced new human antibodies directed against ROBO4 were by a phage display strategy and the antibody selection was performed by using HEK and HEK stably expressing ROBO4 (HEK-ROBO4) cell lines. As a first step, a batch of 6 different antibodies named D3, H3, H9, E11, H11 and G12 was tested for their binding properties. The antibodies were then tested for their ability to inhibit the attachment of tumor cells to osteoblastic cells in monolayers. Finally the inventors showed that the anti-ROBO4 antibodies E11 and G12 inhibits significantly the formation of the tumor spheroid. The present invention thus relates to anti-ROBO4 human monoclonal antibodies and uses thereof for the treatment of cancer.
PURPOSE OF REVIEW: To summarise the evidence regarding which patients might benefit from deprescribing antihypertensive medications.
RECENT FINDINGS: Older patients with frailty, multi-morbidity and subsequent polypharmacy are at higher risk of adverse events from antihypertensive treatment, and therefore may benefit from antihypertensive deprescribing. It is possible to examine an individual's risk of these adverse events, and use this to identify those people where the benefits of treatment may be outweighed by the harms. While such patients might be considered for deprescribing, the long-term effects of this treatment strategy remain unclear. Evidence now exists to support identification of those who are at risk of adverse events from antihypertensive treatment. These patients could be targeted for deprescribing interventions, although the long-term benefits and harms of this approach are unclear.
PERSPECTIVES: Randomised controlled trials are still needed to examine the long-term effects of deprescribing in high-risk patients with frailty and multi-morbidity.
The present invention relates to a composition comprising an extract or fraction of Rosa rugosa Thunb. flower as an active ingredient for preventing, alleviating, or treating inflammatory diseases, and more specifically, to a composition comprising an ingredient selected from an ethanol extract, a hexane fraction, a dichloromethane fraction, an ethyl acetate fraction, a butanol fraction, and a water fraction of Rosa rugosa Thunb. flower as an active ingredient for preventing, alleviating, or treating inflammatory diseases. Pharmaceutical compositions of the present invention can effectively prevent, alleviate, or treat inflammatory diseases without side effects by comprising an extract or a fraction of Rosa rugosa Thunb. flower as an active ingredient. Also, inflammatory diseases can be effectively prevented or alleviated by simply ingesting a health supplement product of the present invention, or a food product containing a food additive of the present invention.
Understanding the relationship between stomatal conductance (gs) and photosynthesis (An) under water stress conditions can improve the accuracy of land surface models for estimating the gas exchange of crop canopies with the atmosphere. However, little is known about the effect of water stress on this relationship in crops. A glasshouse experiment was, therefore, conducted to investigate changes in the linear relationship between gs and An owing to water stress in rice and the association with soil moisture content. Severe (SWS), mild (MWS), and no water stress (NWS) conditions were applied from flowering onwards and the gas exchange in fully developed flag leaves was assessed weekly. The Ball-Woodrow-Berry linear model was used to assess the relationship between gs and An under different treatments. SWS had a significant effect and reduced the slope of the linear relationship between gs and An by 30 % compared with NWS. Only in SWS were An and gs strongly correlated with soil water content. Our study revealed that changes in the linear relationship through a reduction in the slope imply a conservative water-use strategy for rice under intense water stress. We propose that crop models that use the linear relationship should consider the impact of water stress conditions when simulating yields and estimating CO2 and H2O fluxes from crop canopies.
Caspases are a family of cysteine proteases that act as molecular scissors to cleave substrates and regulate biological processes such as programmed cell death and inflammation. Extensive efforts have been made to identify caspase substrates and to determine factors that dictate substrate specificity. Thousands of putative substrates have been identified for caspases that regulate an immunologically silent type of cell death known as apoptosis, but less is known about substrates of the inflammatory caspases that regulate an immunostimulatory type of cell death called pyroptosis. Furthermore, much of our understanding of caspase substrate specificities is derived from work done with peptide substrates, which do not often translate to native protein substrates. Our knowledge of inflammatory caspase biology and substrates has recently expanded and here, we discuss the recent advances in our understanding of caspase substrate specificities, with a focus on inflammatory caspases. We highlight new substrates that have been discovered and discuss the factors that engender specificity. Recent evidence suggests that inflammatory caspases likely utilize two binding interfaces to recognize and process substrates, the active site and a conserved exosite.
BACKGROUND: Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a serine protease inhibitor consisting of multiple domains. A loss of function mutation is described in Netherton patients that show severe symptoms of atopic lesions and itch.
OBJECTIVES: LEKTI domain 6 (LD6) has shown strong serine protease-inhibitory action in in vitro assays and thus it was tested in vitro and in vivo for potential anti-inflammatory action in models of atopic skin disease.
METHODS: Human skin equivalents were treated with LD6 and an inflammatory reaction was challenged by kallikrein-related endopeptidase 5 (KLK5). Furthermore, LD6 was tested on dorsal root ganglia cells stimulated with KLK5, SLIGRL and histamine by calcium imaging. The effect of topically administered LD6 (0.4-0.8%) in lipoderm was compared to a topical formulation of betamethasone-diproprionate (0.1%) in a therapeutic setting on atopic dermatitis-like lesions in NC/Nga mice sensitized to house dust mite antigen. Endpoints were clinical scoring of the mice as well as determination of scratching behaviour.
RESULTS: KLK5 induced an upregulation of CXCL-8, CCL20 and IL-6 in skin equivalents. This upregulation was reduced by pre-incubation with LD6. KLK5 as well as histamine induced calcium influx in a population of neurons. LD6 significantly reduced the calcium response to both stimuli. When administered onto lesional skin of NC/Nga mice, both LD6 and betamethasone-dipropionate significantly reduced the inflammatory reaction. The effect on itch behaviour was less pronounced.
CONCLUSION: Topical administration of LD6 might be a new therapeutic option for treatment of lesional atopic skin.
Insulin resistance arising from Non-Alcoholic Fatty Liver Disease (NAFLD) stands as a prevalent global ailment, a manifestation within societies stemming from individuals' suboptimal dietary habits and lifestyles. This form of insulin resistance emerges as a pivotal factor in the development of type 2 diabetes mellitus (T2DM). Emerging evidence underscores the significant role of hepatokines, as hepatic-secreted hormone-like entities, in the genesis of insulin resistance and eventual onset of type 2 diabetes. Hepatokines exert influence over extrahepatic metabolism regulation. Their principal functions encompass impacting adipocytes, pancreatic cells, muscles, and the brain, thereby playing a crucial role in shaping body metabolism through signaling to target tissues. This review explores the most important hepatokines, each with distinct influences. Our review shows that Fetuin-A promotes lipid-induced insulin resistance by acting as an endogenous ligand for Toll-like receptor 4 (TLR-4). FGF21 reduces inflammation in diabetes by blocking the nuclear translocation of nuclear factor-κB (NF-κB) in adipocytes and adipose tissue, while also improving glucose metabolism. ANGPTL6 enhances AMPK and insulin signaling in muscle, and suppresses gluconeogenesis. Follistatin can influence insulin resistance and inflammation by interacting with members of the TGF-β family. Adropin show a positive correlation with phosphoenolpyruvate carboxykinase 1 (PCK1), a key regulator of gluconeogenesis. This article delves into hepatokines' impact on NAFLD, inflammation, and T2DM, with a specific focus on insulin resistance. The aim is to comprehend the influence of these recently identified hormones on disease development and their underlying physiological and pathological mechanisms.
Subjects will receive buspirone 2.5 mg each morning at the start of the trial. The dose will be increased by 2.5 mg per week in two divided doses daily depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 2.5 mg and the maximum total daily dose will be 30 mg. Medication will be dosed twice daily due to the short half-life (2-3 hours) of this medication.
An Auriculacin soft capsule and its preparation method are disclosed. The Auriculacin soft capsule comprises contents and a capsule skin. The contents are prepared from the following ingredients, by weight, 35-45 parts of an Auricularia Auricula extract, 20-30 parts of a lentinula edodes extract, 15-25 parts of a ginkgo biloba extract, 400 parts of fish oil and 15 parts of beeswax. The capsule skin is prepared from the following ingredients, by weight, 140 parts of gelatin, 70 parts of glycerin, 140 parts of purified water, 0.006 part of black iron oxide and 12.994 parts of caramel pigment. The preparation method comprises the following main steps: 1, pretreatment of raw and auxiliary materials; 2, preparation of a capsule skin feed liquid; 3, preparation of a contents feed liquid; 4, pelleting; 5, shaping; 6, pill washing; 7, drying; and 8, pill selection. The Auriculacin soft capsule has a function of assistance on blood lipid reduction and is aimed at reducing blood fat content and relieving symptoms. The product has clear and definite functions, is safe and practical, has a wide market prospect, and has positive social benefit and economic benefit.
The population around the world is graying, and as many of these individuals will spend years suffering from the burdens of age associated diseases, understanding how to increase healthspan, defined as the period of life free from disease and disability, is an urgent priority of geroscience research. The lack of agreed-upon quantitative metrics for measuring healthspan in aging mice has slowed progress in identifying interventions that do not simply increase lifespan, but also healthspan. Here, we define FAMY (Frailty-Adjusted Mouse Years) and GRAIL (Gauging Robust Aging when Increasing Lifespan) as new summary statistics for quantifying healthspan in mice. FAMY integrates lifespan data with longitudinal measurements of a widely utilized clinical frailty index, while GRAIL incorporates these measures and also adds information from widely utilized healthspan assays and the hallmarks of aging. Both metrics are conceptually similar to quality-adjusted life years (QALY), a widely utilized measure of disease burden in humans, and can be readily calculated from data acquired during longitudinal and cross-sectional studies of mouse aging. We find that interventions generally thought to promote health, including calorie restriction, robustly improve healthspan as measured by FAMY and GRAIL. Finally, we show that the use of GRAIL provides new insights, and identify dietary restriction of protein or isoleucine as interventions that robustly promote healthspan but not longevity in female HET3 mice. We suggest that the routine integration of these measures into studies of aging in mice will allow the identification and development of interventions that promote healthy aging even in the absence of increased lifespan.
FIELD: parapharmaceutical industry. SUBSTANCE: biologically active food additive for prophylaxis and auxiliary treatment of liver diseases on base of immortelle contains ascorbic acid, citric acid and auxiliary substances including sugar. The food additive additionally contains extract of maize stigmas, oat, decoction of burdock roots. Immortelle is used in the form of flowers infusion. The additive contains the following ratio of components, g: infusion of immortelle flowers, 0.002; extract of maize stigmas, 0.01; decoction of burdock roots, 0.002; ascorbic acid, 0.025; citric acid, 0.005; oat, 0.1; auxiliary substances including sugar, the balance up to 0.55. EFFECT: increased therapeutical activity and storage life of product. 2 cl, 2 tbl
The invention relates to the production of phytochemically active extracts from plant material, in particular Petasites hybridus, containing not just lipophilic active agents but also polar or potentially polar components, for example alkaloids, such as pyrrolizidines. The extraction method is characterized in that liquid carbon dioxide in subcritical conditions is used as solvent, as it dissolves the liphohilic agents better than the polar components. Purification of the extract is thus rendered much simpler than in known methods. In this method, preferably at least one pressure-resistant extraction container (10) is used, into which liquid carbon dioxide is introduced in subcritical conditions, and from which a current of extract containing liquid carbon dioxide can be drawn off. In addition, there is at least one zone (160, 180) for treating the liquid carbon dioxide with an adsorbing agent. This zone is situated in the extraction container and/or downstream of said container in a separate pressure-resistant container (16).